Genexine Inc. (KOSDAQ: 095700) and Handok Inc. (KOSPI: 002390), developing a novel long-acting form of recombinant human growth hormone (rhGH), known as GX-H9, for growth hormone deficiency (GHD) patients, today announced that it is scheduled to present at the 99th Annual Meeting of the Endocrine Society for Pediatric Endocrinology (ENDO) on APR 3rd, 2017, at the Orange County Convention Center in Orlando. This presentation will include available multinational Phase 2 data from pediatric GHD and final data from Phase 2 adult GHD during ePost session.
Event: The 99th Annual Meeting of the Endocrine Society for Pediatric Endocrinology(ENDO)
Date: APR 1st – APR 4th, 2017
Location: Orange County Convention Center, Orlando, FL, US
Genexine’s GX-H9, being co-developed with Handok under a strategic partnership, is next-generation, long-acting recombinant human growth hormone (rhGH) consisting of recombinant growth hormone genetically fused to Genexine’s proprietary hybrid Fc (hyFc) platform, giving it extended half-life for more convenient dosing regimen that may lead to improved compliance and better outcome for GHD patients. GX-H9 is being evaluated as weekly and twice-monthly dosing regimens to treat Growth Hormone Deficiency (GHD) in adult and pediatric patients. Both Adult and pediatric GHD trials are comparing GX-H9 to the current daily injection therapy. GX-H9 trials have been receiving government grant funding as one of the top R&D projects by Korean Drug Development Fund. The US FDA Office of Orphan Products Development (OOPD) has granted GX-H9 orphan drug designation for the treatment of growth hormone deficiency in 4Q 2016.
▶About ENDO 2017
ENDO 2017 is the world’s premier event for getting the latest updates in endocrine science and medicine. This is an annual meeting hosted by Endocrine Society which is 100-year-old global membership organization representing professionals from the intriguing field of endocrinology. This year Endocrine Society celebrates its Centennial and honors the profession with sessions highlighting the important advances in the history of endocrinology. More than 9,000 experts including medical doctors, scientists, researchers, and educators will participate for an educational experience and updates covering a broad array of topics about endocrinology. The 99th Annual Meeting of Endocrine Society will be held at APR 1-4, 2017 in Orlando. https://www.endocrine.org/
▶ About Genexine:
Genexine, Inc., listed on KOSDAQ (095700-KQ) since 2009, is a clinical stage biotherapeutics company focused on immuno-oncology and metabolic/autoimmune diseases. Genexine has robust R&D pipelines in clinical and pre-clinical stages based on long-acting Fc fusion technology and therapeutic DNA vaccine technology. In the clinical stage, Genexine has GX-H9 (long-acting human growth hormone, hGH-hyFc) co-developed with Handok for both adult and pediatric GHD, currently in multinational phase II trials. GX-188E therapeutic DNA vaccine for HPV-associated diseases is in Phase II in Europe and Korea for Cervical Intraepithelial Neoplasia II/III and plans to enter into Phase 1b/2a trial in cervical cancer with GX-188E in combination Keytruda (anti- PD-1 therapy) of Merck (also known as MSD) 1H of 2017. Currently Genexine is running over 8 clinical trials from Phase I to Phase IIb in Europe and Asia. In addition to Merck (MSD) collaboration, Genexine has strategic partnerships with leading Asian companies such as Shanghai Fosun Pharma, Tasly Pharma, Kalbe Pharma (largest healthcare Indonesian company), and Korean big Pharma companies such as Handok, Green Cross and Yuhan. Founded in 1999, Genexine has over 150 employees and half of them are scientists with MSc or Ph.D. Genexine is located in Pangyo Techno Valley near Seoul, Korea with a branch office in New York. More information can be found at www.genexine.com
▶ About Handok:
Handok (Chairman & CEO Young-Jin Kim), listed on KOSPI(002390) is a leading innovation-driven pharmaceutical/health-care company in Korea. Handok develops, manufactures and distributes healthcare solutions to improve the health and quality of human life. Handok has a core business focus on diabetes, cardiovascular, muscular skeletal, psychoneurotic disease, human vaccines, medical devices, diagnostics and consumer health. Handok, founded in 1954, grew as a joint venture with Hoechst/Aventis/Sanofi from 1964 to 2012. Handok has also established strategic collaborations in several areas with multiple multinational pharmaceutical companies. More information can be found at www.handok.co.kr
▶ About Korea Drug Development Fund (KDDF):
Established in September 2011, the Korea Drug Development Fund (KDDF), a consortium of three health-related Korean Ministries – the Ministry of Science, ICT, and Future Planning; the Ministry of Trade, Industry, and Energy; and the Ministry of Health and Welfare – is a government-initiated drug development program, which aims to transform Korea into a global leader for new drug development and to enhance national competitiveness in the global arena. More information can be found at www.kddf.org.